The GLP-1 Problem: What Employers Need to Know Before It Hits Your Health Plan.

One drug category is quietly reshaping employer healthcare costs.

Here's how to get ahead of it.

If you haven't started talking about GLP-1 medications yet, your next renewal will force the conversation. Drugs like Ozempic, Wegovy, Mounjaro, and Trulicity have moved from clinical buzzwords to household names, and with that cultural shift has come an explosion in utilization that is now showing up directly in employer health plan costs.

This isn't a future problem. It's a present one. And for employers who still don't have a clear GLP-1 coverage strategy, the financial exposure is growing every month.

The Cost Reality

GLP-1 agonists were originally developed to treat type 2 diabetes, and most health plans have long covered them for that purpose. What's changed is the scale of demand for GLP-1s as weight-loss medications — and the price tag that comes with it.

A single GLP-1 prescription can run around $1,000 per month. For one employee, that's roughly $12,000 per year, potentially more than the total annual premium paid for that individual's coverage. Now multiply that across even a fraction of your workforce, and the math becomes difficult very quickly.

The numbers bear this out. According to the 2025 KFF Employer Health Benefits Survey, among the largest employers (those with 5,000 or more workers) 59% say their GLP-1 costs have already exceeded expectations, and 66% report that covering these medications has had a "significant" impact on their health plan's prescription drug spending. 

This is precisely the kind of high-cost claims driver that makes up a disproportionate share of total healthcare spend — and exactly what a proactive cost management strategy is designed to address before it becomes unmanageable.

Why This Is Harder Than It Looks

The challenge with GLP-1s isn't just cost… it's complexity. 

These medications sit at the intersection of several overlapping issues: medical necessity, chronic disease management, employee expectations, and plan design.

There's no clean, one-size-fits-all answer.

Here's what makes the decision particularly tricky: GLP-1s are an effective and legitimate treatment for diabetes and obesity, which are themselves significant drivers of downstream healthcare costs — cardiovascular disease, kidney disease, joint problems, and more. Covering these medications may prevent far more expensive claims down the road. At the same time, the sheer volume of demand and the long-term nature of the treatment (discontinuing the medication often reverses the weight loss) means the liability is open-ended in a way few other drug categories are.

Employers who ignore the issue and don't build a defined strategy are essentially writing a blank check. Those who apply a blunt exclusion may create gaps in care for employees with legitimate medical needs. 

The path forward is deliberate, data-driven plan design, not avoidance and not unlimited access.

What Smart Employers Are Doing

There is no single right answer on GLP-1 coverage, but there are proven strategies that allow employers to manage cost exposure without abandoning employees who genuinely need these medications.

Here's what forward-thinking employers and their healthcare partners are implementing:

Require a Holistic Weight-Management Program

One of the core problems with GLP-1s for weight loss is that the results are often medication-dependent, meaning when patients stop taking the drug, weight frequently returns. This creates perpetual utilization with no endpoint.

Employers who are covering GLP-1s for weight loss are increasingly requiring concurrent enrollment in a structured lifestyle program — including nutritional guidance, exercise plans, and behavioral coaching. This approach enhances the medication's effectiveness, supports long-term outcomes, and creates a framework that isn't solely drug-dependent.

Employees who build sustainable habits alongside medication have a better chance of maintaining results if they eventually stop treatment.

Set Clear Clinical Criteria

Not every employee requesting a GLP-1 for weight loss should automatically qualify.

Experts recommend establishing defined criteria for coverage eligibility. For example, requiring a BMI of 33 or higher alongside at least one related comorbidity such as hypertension, type 2 diabetes, heart disease, chronic obstructive pulmonary disease, or a respiratory condition.

Tying coverage to clinical thresholds ensures that the benefit reaches the employees with the greatest medical need and the highest potential for downstream cost reduction, rather than functioning as an open-access weight-loss benefit.

Implement Lifetime or Time-Based Limits

Some employers are capping their GLP-1 exposure through spending limits — commonly in the $10,000 to $20,000 range — or time-based limits such as a two-year coverage window. This provides a defined boundary on liability while still making the benefit accessible to employees who need it.

Use Pharmacy Benefit Management Strategically

Brand recognition has driven a disproportionate share of GLP-1 utilization toward

Ozempic specifically, not because it's clinically superior, but because it's the most recognized name. Employers working with pharmacy benefit managers (PBMs) can steer utilization toward clinically equivalent but less demand-driven alternatives, reducing spend while preserving appropriate access for members who depend on GLP-1s for diabetes management.

Higher copays or plan deductibles applied specifically to this drug category are another tool, giving plan sponsors flexibility in how they structure cost sharing.

Apply Step Therapy

Step therapy (sometimes called "fail-first") requires that employees try lower-cost treatment options before accessing higher-cost alternatives. For weight management, this might mean documented participation in a supervised diet and exercise program before GLP-1 coverage is approved. This is a standard medical management technique and a reasonable safeguard against immediate, unrestricted access to the most expensive option.

Consider Bariatric Surgery as an Alternative

It may seem counterintuitive, but covering bariatric surgery can be a more cost-effective long-term option than open-ended GLP-1 coverage. The procedure typically costs between $10,000 and $15,000 — comparable to a single year of GLP-1 prescriptions — and according to the Cleveland Clinic, bariatric surgery is overall more effective than GLP-1 medication. For eligible employees, this may represent a more permanent solution at a more predictable cost.

What Employers Need to Understand About Their Options

Currently, neither self-funded nor fully insured group health plans are required to cover GLP-1 medications for weight loss. Plan sponsors have meaningful flexibility in how they structure this benefit, including whether to cover it at all, what clinical criteria to require, and how to manage utilization.

That said, because GLP-1s are also a primary treatment for type 2 diabetes, wholesale exclusion of the entire drug class requires careful plan design to ensure employees with legitimate diabetes-related needs are not left without access to necessary medication.

This is exactly the kind of nuanced, high-stakes plan design decision that requires a knowledgeable healthcare cost management partner — not a standard broker renewal conversation.

The 2025 KFF survey also signals what's coming: with drug prices flagged by more than a third of large employers as a top driver of premium growth, and GLP-1 utilization continuing to rise, the window to build a proactive strategy is narrowing. Employers who address this now, with defined policies and integrated cost containment, are in a far stronger position than those who wait for the cost to appear in their renewal.

The Bottom Line

GLP-1 medications represent one of the most significant cost management challenges employers have faced in years. They're clinically meaningful, employee-visible, and financially open-ended without a clear strategy in place. The answer isn't to ignore them and the answer isn't to cover them without guardrails.

The answer is what it always is in healthcare cost management: data, transparency, and deliberate plan design built around your specific workforce and cost drivers.

This isn't a decision that should be made reactively at renewal time. It should be part of a proactive, year-round approach to managing the high-cost claims that are driving your premiums — with a partner who has the expertise to help you build the right policy before the cost shows up on your books.

A defined GLP-1 strategy today means no surprises at renewal. Let's talk.

Sources: 2025 KFF Employer Health Benefits Survey (October 22, 2025); KFF News Release, "Annual Family Premiums for Employer Coverage Rise 6% in 2025"; Cleveland Clinic (bariatric surgery outcomes); Cleveland Clinic “New Study Finds Bariatric Surgery Associated with Greater Benefits Than GLP-1RAs Alone”